THE OSTEOSARCOMA INSTITUTE

The osteosarcoma institute executed agreements to fund two grants for a total of $1,300,000 for a clinical trial and correlative study with the dana farber cancer institute. $306,500 of this was funded in 2024.

The osteosarcoma institute executed an agreement to fund a translational research grant for a total of $500,000 with bc cancer. $283,333 of this grant was funded in 2024.

The osteosarcoma institute executed an agreement to fund a translational research grant for a total of $500,000 with european molecular biology laboratory. $125,000 of this grant was funded in 2024.

The osteosarcoma institute executed an agreement to fund a translational research grant for a total of $500,000 with northwestern university. $125,000 of this grant was funded in 2024.

The osteosarcoma institute executed an agreement to fund correlative studies for a total of $220,000 with stanford university. $110,000 of this grant was funded in 2024.

The osteosarcoma institute executed an agreement to fund a translational grant for a total of $401,411 with university of minnesota. $101,411 of this was funded in 2024.

The osteosarcoma institute executed an agreement to fund a translational grant for a total of $500,000 with baylor college of medicine. $125,000 of this was funded in 2024.

The osteosarcoma institute executed an agreement to fund a translational grant for a total of $500,000 with weill medical college of cornell university. $125,000 of this was funded in 2024.

Other program services expenditures not directly allocable to the twelve on-going research grants during the current year including expenditures of $18,821 for the osi connect program. The osi connect program is a free, patient-centered service offered by the osterosarcoma institute that connects individuals affected by osteosarcoma with expert physicians to answer questions about the disease. The negative $100,000 was a return of a grant payment associated with a canceled grant from 2023.